Day: August 19, 2020

ANNOUNCEMENT NO. 20 – 19 AUGUST 2020 Attached please find the full interim report as PDF fileToday, the Board of Directors approved the interim report for the second quarter of 2020. The report contains the following highlights:ResultsAdjusted Result* for Q2 2020: USD 29 (Q2 2019: USD -12 million)Assset Management: USD 11 million (USD -3 million)Dry Operator: USD -4 million (USD -6 million)Tanker Operator: USD 22 million (USD -3 million)Adjusted Result for H1 2020: USD 58 million (H1 2019: USD -5 million)*”Profit/loss for the period” adjusted for “Profit from sale of vessels etc.”MarketsAsset prices affected by market uncertainty and declined significantly during the quarter.Dry Cargo: Very weak spot market with Supramax and Panamax rates 34% lower than Q2 2019Tankers: Significant spike in spot rates in April and May due to oil...

MEDDELELSE NR. 20 – 19. AUGUST 2020 Rapporten er vedhæftet som PDF-fil i sin fulde ordlyd.Bestyrelsen har i dag godkendt Delårsrapporten for 2. kvartal og 1. halvår 2020. Delårsrapporten, der kun udgives på engelsk, er vedhæftet som PDF-fil og har følgende hovedpunkter:ResultaterJusteret perioderesultat* 2. kvartal 2020:  USD 29  (2. kvartal 2019: USD -12 mio.)Asset Management: USD 11 million (USD -3 million)Dry Operator: USD -4 mio. (USD -6 mio.)Tanker Operator: USD 22 mio. (USD -3 mio.)Justeret perioderesultat* 1. halvår 2020: USD 58 mio. (1. halvår 2019: USD -5 mio.)* ”Periodens resultat” justeret for “Salgsavancer og -tab, skibe m.v.”MarkederSkibsværdier påvirket af usikkerhed i markedet og faldt væsentligt i løbet af kvartalet.Tørlast: Meget svagt spotmarked med Supramax- og Panamax-rater 34% lavere end i 2. kvartal 2019.Tank:...

FansUnite announced closing of oversubscribed brokered private placement of $5,009,846 CAD

VANCOUVER, Washington, Aug. 18, 2020 (GLOBE NEWSWIRE) — CytoDyn Inc. (OTC.QB: CYDY), (“CytoDyn” or the “Company”), a late-stage biotechnology company developing leronlimab (PRO 140), a CCR5 antagonist with the potential for multiple therapeutic indications, announced today David F. Welch, Ph.D. has advised the Company he has chosen not to stand for re-election to the Company’s Board of Directors at its upcoming annual meeting of stockholders. Dr. Welch joined CytoDyn’s Board in January 2019 and currently serves as Chair of its Compensation Committee. Dr. Welch is Founder and Chief Innovation Officer of Infinera Corporation, a Nasdaq-listed global supplier of networking equipment, software and services.Regarding his decision, Dr. Welch, stated, “I understood the potential of CytoDyn some time ago and began investing before...

NASDAQ OMX Copenhagen A/SBørsmeddelelse nr. 2020/15Aalborg 19. august 2020Aalborg Boldspilklub A/S har med øjeblikkelig virkning solgt 26-årige Patrick Olsen til AGF.Patrick Olsen, der sidste sommer blev hentet til AaB fra FC Helsingør i 2. division, havde kontrakt med AaB indtil 30. juni 2023, men AaB og Patrick Olsen har valgt at takke ja til et købstilbud fra den aarhusianske klub.Patrick Olsen opnåede 40 officielle kampe og ni scoringer for Hele Nordjyllands Hold.På baggrund af salget af Patrick Olsen opjusterer AaB resultatforventningerne for 2020 fra et resultat før skat i niveauet mellem et nulresultat og minus 5 mio. kr. til et resultat i niveauet plus 3 mio kr. og minus 2 mio. kr.Heri er indregnet fortsat investering i spillertruppen og strategiske investeringer i den kommercielle udvikling. Administrerende direktør

The Danish Financial Supervisory AuthorityNasdaq Copenhagen A/SH1 2020 highlightsVestjysk Bank reported profit after tax of DKK 142 million in H1 2020. The reported profit was adversely affected by the impact of the Corona crisis on the Bank’s impairment provisions, based on a management estimate. The Bank increased impairment provisions by an additional DKK 60 million in Q2 in light of the Corona crisis and the uncertainty concerning Britain’s exit from the EU (Brexit). The Bank has thus made a total impairment provision of DKK 200 million for economic uncertainty, corresponding to 2.1% of the Bank’s net loans and advances.Profit after tax was DKK 142 million (H1 2019: DKK 163 million), for an annualised return on equity after tax of 9.5%.Core income of DKK 425 million (H1 2019: DKK 453 million).Market value adjustments of DKK 14 million...

FinanstilsynetNasdaq Copenhagen A/SHovedpunkter for 1. halvår 2020Vestjysk Bank realiserede i 1. halvår 2020 et resultat efter skat på 142 mio. kroner. Resultatet er negativt påvirket af Corona-krisens indvirkning på bankens nedskrivninger i form af et ledelsesmæssigt skøn. Banken har i 2. kvartal 2020 øget nedskrivningerne til Corona-krisen og usikkerhed omkring Storbritanniens udtræden af EU (Brexit) med yderligere 60 mio. kroner. Herefter er der i alt afsat 200 mio. kroner til økonomisk usikkerhed, hvilket svarer til 2,1% af bankens nettoudlån.Resultat efter skat udgør 142 mio. kroner (163 mio. kroner i 1. halvår 2019), hvilket giver en forrentning af egenkapitalen på 9,5% p.a. efter skat.Basisindtægter på 425 mio. kroner (453 mio. kroner i 1. halvår 2019).Kursreguleringer udgør 14 mio. kroner (20 mio. kroner i 1. halvår 2019).Omkostningsprocent...

HONG KONG, Aug. 19, 2020 (GLOBE NEWSWIRE) — Futu Holdings Limited (“Futu” or the “Company”) (NASDAQ: FUTU), a leading one-stop financial technology platform in China, today announced the pricing of the offering of 9,500,000 American depositary shares (the “ADSs”), each representing eight Class A ordinary shares of the Company (the “ADS Offering”), at a price of US$33.00 per ADS. The Company will grant the underwriters in the ADS Offering a 30-day option to purchase up to an additional 1,425,000 ADSs.Goldman Sachs (Asia) L.L.C., Credit Suisse Securities (USA) LLC, UBS Securities LLC and Haitong International Securities Company Limited are acting as joint bookrunners for the ADS Offering.The ADSs are offered under the Company’s shelf registration statement on Form F-3 (the “Form F-3”) which was filed with the Securities and Exchange...

Oslo (Norway), 19 August 2020 – PCI Biotech (OSE: PCIB), a cancer focused biopharmaceutical company, today announced that a case report series from the Phase I study with PCI Biotech’s proprietary drug fimaporfin (AmphinexTM), for the treatment of inoperable extrahepatic bile duct cancer (eCCA), is accepted for publishing in Endoscopy International Open. The article has the title “Photochemical Internalisation and gemcitabine combined with first-line chemotherapy in perihilar cholangiocarcinoma – observations in three patients” and will soon be available online.Professor Jörg Trojan, one of the key investigators in the Phase I trial and global coordinating investigator for the pivotal RELEASE study, said: “These selected cases from the Phase I study are really encouraging and nicely demonstrates the apparent positive...